Home / Vaccines & Immunizations (page 3)

Vaccines & Immunizations

Takeda to Develop Zika Vaccine with up to $312 Million in Funding from US Government

OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) today announced that BARDA, the Biomedical Advanced Research and Development Authority, has selected Takeda’s Vaccine Business Unit to develop a vaccine to support the Zika response in the US and affected regions around the world. Initial funding from BARDA, which is …

Read More »

Merck and Moderna Partner to Advance Novel Personalized Cancer Vaccines with Keytruda for Multiple Types of Cancer

KENILWORTH, N.J. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Moderna Therapeutics today announced a strategic collaboration and license agreement to develop and commercialize novel messenger RNA (mRNA)-based personalized cancer vaccines. The collaboration will combine Merck’s established leadership in immuno-oncology with Moderna’s pioneering …

Read More »

AXON’s Alzheimer’s Vaccine Starts Mid-Stage Trial

BRATISLAVA, Slovakia–(BUSINESS WIRE)–AXON Neuroscience announced the successful start of the ADAMANT phase II study, as the first patient has been vaccinated with the active tau vaccine. AXON’s vaccine, AADvac1, is intended to be the first disease-modifying tau vaccine for Alzheimer’s disease. ADAMANT PHASE II CLINICAL STUDY ADAMANT is a 24-month, …

Read More »

Pfizer Joins the Human Vaccines Project to Help Decode the Immune System

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today announced it will join the Human Vaccines Project (the Project), a public-private consortium focused on cross-sector collaboration to identify human immune responses associated with optimal vaccine protection. Insights gained will guide the development of potentially improved vaccines against diseases such as influenza, dengue, HIV …

Read More »

Sanofi and Merck End Joint Vaccines Venture in Europe

KENILWORTH, N.J. & LYON, France–(BUSINESS WIRE)–Sanofi Pasteur and Merck, known as MSD outside the United States and Canada, today announced their intent to end their joint vaccines operations in Europe. Upon concluding their joint venture, both companies plan to integrate their respective European vaccine businesses into their operations, independently manage …

Read More »

Hemispherx Biopharma Exploring Possible Research Programs in Zika Virus

Philadelphia, PA, Tuesday, February 09, 2016: Hemispherx Biopharma, Inc. (NYSE MKT: HEB) announced today that it is beginning to consider study designs for potential tests of the activity and potential uses of its natural alpha interferon (Alferon® N and Alferon® LDO) and rintatolimod (Ampligen®) drug formulations against the Zika virus. The …

Read More »

City of Hope and Fortress Biotech Form DiaVax Biosciences to Develop New Vaccines

A new company has been formed to develop two novel vaccines against cytomegalovirus (CMV) infection, a life-threatening illness in people with weakened or underdeveloped immune systems, such as cancer patients and developing fetuses. City of Hope and Fortress Biotech have reached an agreement to form the new subsidiary company, called …

Read More »

Bristol-Myers Squibb Signs a Prostate Cancer Vaccine Deal with Bavarian Nordic

Bristol-Myers Squibb Co. (BMS) said that it has entered into a $1 billion deal with Danish biotechnology company Bavarian Nordic for rights to a late-stage prostate cancer vaccine. The companies entered into an agreement that provides BMS an exclusive option to license and commercialize Prostvac, Bavarian Nordic’s investigational Phase III …

Read More »